Joanne Igoli, Jeremiah Oluwatomi Itodo Daniel, Halleluyah Oludele, Adedoyin Esther Alao, Idemudia Stephen Ogedegbe, Adewale Olaniyan, Michael Adeshola Adebayo, Damilola Matthew, Temidayo Elizabeth Oyepitan, Daniel Brabi, Olatomiwa Olukoya, Temidayo Osunronbi
{"title":"Serum fibrinogen level and fibrinogen administration in patients with traumatic brain injury: a systematic review and meta-analysis protocol","authors":"Joanne Igoli, Jeremiah Oluwatomi Itodo Daniel, Halleluyah Oludele, Adedoyin Esther Alao, Idemudia Stephen Ogedegbe, Adewale Olaniyan, Michael Adeshola Adebayo, Damilola Matthew, Temidayo Elizabeth Oyepitan, Daniel Brabi, Olatomiwa Olukoya, Temidayo Osunronbi","doi":"10.1101/2024.08.26.24312610","DOIUrl":null,"url":null,"abstract":"<strong>Introduction</strong> Traumatic Brain Injury (TBI) is a leading cause of disability and death globally. It has a significant economic burden. Coagulopathy has been identified as one of the key factors contributing to the poor outcomes observed in TBI patients, and it has been theorised that the management of coagulopathy will improve patient outcomes. Low serum fibrinogen levels denote a coagulopathic state, and the therapeutic administration of fibrinogen has been proposed to correct this state. However, there is no consensus on its efficacy in patients with TBI.","PeriodicalId":501513,"journal":{"name":"medRxiv - Nephrology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.26.24312610","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction Traumatic Brain Injury (TBI) is a leading cause of disability and death globally. It has a significant economic burden. Coagulopathy has been identified as one of the key factors contributing to the poor outcomes observed in TBI patients, and it has been theorised that the management of coagulopathy will improve patient outcomes. Low serum fibrinogen levels denote a coagulopathic state, and the therapeutic administration of fibrinogen has been proposed to correct this state. However, there is no consensus on its efficacy in patients with TBI.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
